Merck & Co., Inc.
http://www.merck.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Merck & Co., Inc.
Progress In Pharma’s Slow Battle Against A Deadly Infant Virus
Pfizer is up against AstraZeneca and Sanofi in developing competing approaches to tackling the unmet need in respiratory syncytial virus (RSV). But earlier failures mean all players will need much more data to sway regulators.
August User Fee Calendar Features Gene Therapy, Analgesics, And Of Course Oncology
Sixteen applications are in line for US FDA decisions in August. Ten are novel agents.
Merck Outlines COVID-19 Vaccine And Antiviral Plans As Pandemic Dents Q2 Sales
The expectation of a big second quarter sales decline proved true, but the situation is improving. Meanwhile, Merck & Co. is advancing two vaccines and an antiviral against the novel coronavirus.
Merck & Pfizer Win English Funding For Kidney Cancer Combo
NICE says that Bavencio plus Inlyta will be made available via the Cancer Drugs Fund for advanced kidney cancer while more evidence is collected to support the combination therapy's routine use on the National Health Service.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Abmaxis
- Acacia Biosciences
- Afferent Pharmaceuticals
- ArQule, Inc.
- Avecia Biologics Limited
- Banyu Pharmaceutical Co., Ltd.
- Calporta Therapeutics
- cCAM Biotherapeutics Ltd.
- Cubist Pharmaceuticals, Inc. (Adolor Corporation (ADLR)
- Calixa Therapeutics, Inc.
- Optimer Pharmaceuticals, Inc.
- Trius Therapeutics, Inc.)
- Idenix Pharmaceuticals, Inc.
- Immune Design Corporation
- Inspire Pharmaceuticals, Inc.
- IOmet Pharma
- iOnctura SA
- Integrated Therapeutics Group
- Merck Sharp & Dohme (MSD) Pharmaceuticals Pvt. Ltd.
- MSD K.K. (Japan)
- Nobilon International BV
- Novacardia
- OncoEthix SA
- Organon BioSciences
- Peloton Therapeutics, Inc.
- Rigontec GmbH
- Schering-Plough Corporation
- SmartCells, Inc.
- Tilos Therapeutics, Inc.
- Vallee S.A.
- Viralytics Limited (ASX:VLA)
- Themis Biosciences GmbH